

Table 11. Incidence of gastric ulcers with alendronate, aspirin, and placebo

Study	Regimens	Treatment Duration	N	Endpoints	Results
Lanza et al ¹⁵	Alendronate: 5 mg/d 10 mg/d Aspirin: 650 g QID placebo	14 days	95	Esophageal, gastric, and duodenal endoscopic scores. Incidence of gastric erosions at days 8 and 15.	There were no significant differences between the placebo group and the alendronate groups. However, there were significant differences in all endoscopic endpoints at days 8 and 15 for the aspirin group when compared to placebo. There was a combined total of two patients (~ 4.7%) in both alendronate groups with a gastric score greater than 4. In comparison, there were 10 patients (71.4%) in the aspirin group with a score greater than 4. The sample size for this study was small. Merck (Fosamax) funded the study.